Sana Biotechnology, Inc.
SANAHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. The $901.7M market capitalization puts SANA squarely in small-cap range for its industry. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Market Cap
$901.7M
Beta
2.18
P/E (TTM)
—
P/E (Fwd)
-6.02
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.54
ROE
-147.4%
ROA
-27.5%
Cash
$101.1M
Total Debt
$82.6M
Free CF
-$29.7M
52W Change
39.7%
Annual Financials
Cash vs Debt
With $101.1M in cash and $82.6M in debt, SANA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$29.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -147.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, SANA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SANA.